QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital(TM) PCR Platform and Establish Commercial Operations by 2011

PLEASANTON, California, December 10, 2010 - QuantaLife, Inc. announced today that it has closed a $17.2M Series B
financing. The majority of the proceeds will be used to establish commercial
operations for introduction of its first product, the Droplet Digital(TM) PCR
platform, into the life sciences research market early next year and
accelerate development of targeted diagnostic tests. Paladin Capital Group,
together with other existing investors reiterated their strong support and
was joined by Merieux Developpement and Vital Financial LLC, as new
investors. According to Dr. Bill Colston, Founder and Chief Executive Officer
of QuantaLife, "Droplet Digital PCR establishes a new standard for nucleic
acid measurement, including the absolute quantification of DNA, RNA, and
miRNA. It has a myriad of potential uses - in the research laboratory and in
the clinic. With the completion of this financing, we have diversified our
world-class investor base and are well positioned for a successful transition
to commercialization. We look forward to bringing a cost-effective and
reliable product to the research community."

"QuantaLife's technology is very compelling and represents a unique
opportunity to establish a new standard for the future of genomics research
and nucleic acid testing, with a simple, reliable and cost-effective
solution. We look forward to working with QuantaLife's management team and
existing shareholders to help establish the company as a global leader in the
emerging digital PCR market," said Francois Valencony, Managing Director of
Merieux Developpement.

About QuantaLife, Inc.

QuantaLife has developed 3rd generation PCR technology that quantifies
DNA molecules by Droplet Digital PCR. Droplet Digital PCR measures target
nucleic acid target molecules with unrivaled absolute quantitative resolution
and sensitivity. Applications include copy number variation (CNV), mutation
detection, and gene expression analysis. The company's mission is to provide
tools that accelerate new strategies for the diagnosis and treatment of
inherited disorders, cancer, and infectious disease.

About Paladin Capital Group

Paladin Capital Group is an established, multi-stage private equity firm
that invests in growing companies through acquisitions and expansion capital.
Headquartered in Washington D.C., with offices in New York City and Atlanta,
GA, Paladin has more than $950 million of committed capital across several
distinct funds.

About Merieux Developpement

Merieux Developpement is the healthcare investment company of Institut
Merieux, a French industrial holding company dedicated to biology, which
currently employs more than 10,000 people worldwide. Institut Merieux has
majority ownership of bioMerieux (NYSE Euronext, BIM), Silliker, Transgene
(NYSE Euronext, TNG) and ABL Inc. Merieux Developpement intends to invest up
to euro 70 million as minority shareholder from 2010 to 2013 in the field of
healthcare on a global basis, working alongside entrepreneurs and innovative
companies whose products and services can bring genuine advances to the
health of patients and consumers worldwide. More information can be found at
www.merieux-developpement.com

Mike Lucero of QuantaLife, Inc., +1-650-823-6366, mike at quantalife.com